Our finding on BMI concurred with the TriMaster clinical trial on DPP-4 and SGLT-2 as second- or third-line therapy among T2D patients on metformin monotherapy or metformin and SU therapy. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.